Latest News for: phase 1 clinical trial
Edit
Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a ...
Nasdaq Globe Newswire 28 Apr 2026
Edit
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for ...
Nasdaq Globe Newswire 28 Apr 2026
Edit
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer (Form 8-K) (Silexion Therapeutics Corp)
Public Technologies 28 Apr 2026
) Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to ... "The successful submission of our Phase 2/3 clinical trial application to Germany is a defining ...
Edit
Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord ...
Canada Newswire 27 Apr 2026
Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2 clinical trial, for the treatment of aplastic anemia ... The Phase 2 multicenter, open-label study ... CK0801 Phase 1 Trial Outcomes.
Edit
Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia
PR Newswire 27 Apr 2026
Phase 2 multicenter, open-label study ... Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2 clinical trial, for the treatment of aplastic anemia ... CK0801 Phase 1 Trial Outcomes.
Edit
Early Phase Clinical Trial Outsourcing Research Report 2026: $14.8 Bn Market Opportunities, Trends, Competitive Landscape, ...
Nasdaq Globe Newswire 24 Apr 2026
The early phase clinical trial outsourcing market presents opportunities driven by rising personalized medicine focus, ...
Edit
Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment ...
Nasdaq Globe Newswire 23 Apr 2026
Edit
Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)
Pharmiweb 23 Apr 2026
Edit
Site Management Organization Market Report 2026-2035 with Insights by Therapeutic Area, Trial Phases, Clinical Trial ...
Nasdaq Globe Newswire 20 Apr 2026
Edit
The Galveston Daily News
20 Apr 2026
Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases
Edit
The Joplin Globe
20 Apr 2026
PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner
Edit
The Eagle-Tribune
20 Apr 2026
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV108, an
Edit
Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases (Asahi Kasei Corporation)
Public Technologies 20 Apr 2026
Asahi Kasei, a diversified global company, today announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound developed to address significant unmet ...
Edit
Luye Pharma Announces First Subject Enrolled in China Phase Ⅱ Clinical Trial of LY03017 (5-HT2AR/5-HT2CR) for Alzheimer’s ... (Luye Pharma Group Ltd)
Public Technologies 16 Apr 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 130968584) .
- 1
- 2
- Next page »